IgG4-related disease - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱ 6 min read ✅ Medically reviewed

Overview

IgG4‑related disease (IgG4‑RD) is a systemic, immune‑mediated condition characterized by dense infiltration of IgG4‑positive plasma cells and often elevated serum IgG4 levels. It can affect virtually any organ, leading to swelling, fibrosis (hardening), and loss of function. The disease was first recognized in the early 2000s in patients with autoimmune pancreatitis and has since been identified in the pancreas, salivary glands, orbit, kidneys, lungs, aorta, lymph nodes, and many other sites.

  • Who it affects: Most patients are men aged 50–70 years, but women and younger individuals can be affected. Certain organ manifestations (e.g., autoimmune pancreatitis) show a slight male predominance, whereas others (e.g., sialadenitis) have a more balanced gender distribution.
  • Prevalence: Exact prevalence is uncertain because the disease is under‑recognized, but recent population‑based studies estimate an overall prevalence of 0.28–0.5 per 100,000 persons in Western countries, with higher rates in Asian cohorts (up to 1.5 per 100,000). The incidence appears to be rising as awareness improves.

IgG4‑RD is considered a chronic condition that often requires long‑term monitoring and, in many cases, lifelong therapy to prevent relapses.

Symptoms

Symptoms depend on the organ(s) involved. The hallmark is a painless, swelling‑like mass that can mimic cancer or infection. Below is a comprehensive list of common presentations:

Head and Neck

  • Swelling of salivary glands (sialadenitis): painless enlargement of the parotid or submandibular glands.
  • Orbital disease: proptosis (bulging eye), diplopia (double vision), or a palpable mass around the eye.
  • Riedel’s thyroiditis: hard, painless thyroid with possible dysphagia or hoarseness.

Pancreas & Biliary Tract

  • Acute or chronic abdominal pain.
  • Jaundice due to bile‑duct obstruction.
  • Weight loss and steatorrhea (fatty stools) if exocrine function is impaired.

Kidneys

  • Flank pain or vague abdominal discomfort.
  • Proteinuria or hematuria detected on urine tests.
  • Progressive renal insufficiency.

Lung & Mediastinum

  • Dry cough, shortness of breath, or wheezing.
  • Chest pain or mediastinal mass on imaging.

Vasculature & Aorta

  • Back or abdominal pain from aortitis.
  • Pulsatile mass, aneurysm formation, or sudden rupture (rare but life‑threatening).

General/Systemic

  • Low‑grade fever or fatigue.
  • Unexplained weight loss.
  • Elevated serum IgG4 (often >135 mg/dL) though normal levels do not exclude the disease.

Causes and Risk Factors

The precise trigger for IgG4‑RD is still being researched. Current evidence points to a dysregulated immune response involving both innate and adaptive pathways.

Potential Etiologic Factors

  • Autoimmune mechanisms: T‑helper 2 (Th2) cytokines (IL‑4, IL‑13) and regulatory T‑cells promote IgG4‑producing plasma cells.
  • Allergic background: Many patients have a history of atopy, asthma, or eosinophilia, suggesting a link to allergic pathways.
  • Genetic predisposition: Certain HLA alleles (e.g., HLA‑DRB1*04:06) are over‑represented in Asian cohorts.
  • Infections: Some case series propose chronic viral (e.g., hepatitis C) or bacterial exposure as a possible trigger, though data are inconsistent.

Risk Factors

  • Male sex, especially ages 50–70.
  • Asian ethnicity (higher reported incidence).
  • Co‑existing autoimmune diseases (e.g., Sjögren’s syndrome, rheumatoid arthritis).
  • History of allergic disease or elevated eosinophil counts.

Diagnosis

Diagnosing IgG4‑RD requires a combination of clinical, serologic, radiologic, and histopathologic data. No single test is definitive.

Clinical Criteria

Several expert groups (e.g., the Japanese Society of Internal Medicine, American College of Rheumatology/EULAR) propose diagnostic criteria that include:

  1. Characteristic organ enlargement or nodular lesions.
  2. Serum IgG4 concentration >135 mg/dL (optional, as >50% of patients may have normal levels).
  3. Histopathology showing dense lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis with >10 IgG4‑positive plasma cells per high‑power field (HPF) and an IgG4/IgG ratio >40%.
  4. Response to glucocorticoid therapy (supportive but not required).

Laboratory Tests

  • Serum IgG4 level (ELISA). Elevated in ~60–70% of patients.
  • Complete blood count – may reveal eosinophilia.
  • Renal and liver function panels, fasting glucose (especially if pancreas involved).
  • Autoimmune panels (ANA, rheumatoid factor) to exclude mimickers.

Imaging Studies

  • CT or MRI: organ‑specific enlargement, “sausage‑shaped” pancreas, diffuse lung infiltrates, or aortic wall thickening.
  • PET‑CT: increased FDG uptake in affected sites, useful for assessing disease extent.
  • Ultrasound: helpful for salivary gland or thyroid involvement.

Biopsy (Gold Standard)

Core needle or excisional biopsies provide tissue for histology. Pathologists look for the three hallmarks mentioned above. Immunostaining for IgG4 and total IgG quantifies the IgG4/IgG ratio.

Differential Diagnosis

Conditions that can mimic IgG4‑RD include malignancies (e.g., lymphoma, carcinoma), other autoimmune diseases (e.g., Sjögren’s, sarcoidosis), infectious granulomas, and drug‑induced fibrosis. Careful correlation of clinical, serologic, and histologic data is essential.

Treatment Options

Therapy aims to reduce inflammation, prevent fibrosis, and preserve organ function. Treatment is individualized based on disease severity, organ involvement, and comorbidities.

First‑Line: Glucocorticoids

  • Initial regimen: Prednisone 0.6–1.0 mg/kg/day (usually 30–40 mg) for 2–4 weeks.
  • Tapering: Gradual reduction over 3–6 months to the lowest effective dose.
  • Most patients experience rapid symptom improvement (within weeks).

Steroid‑Sparing Agents

Because long‑term steroids cause significant side effects, immunomodulators are often added.

  • Rituximab (anti‑CD20 monoclonal antibody): Effective in refractory disease or when steroids are contraindicated. Typical dose 375 mg/mÂČ weekly ×4 or 1 g two weeks apart.
  • Azathioprine, Mycophenolate mofetil, or Methotrexate: Used as maintenance therapy; doses titrated to tolerance.
  • Cyclophosphamide: Reserved for severe, organ‑threatening disease (e.g., aortitis) due to toxicity.

Procedural Interventions

  • Endoscopic drainage or stenting: For biliary obstruction from IgG4‑related sclerosing cholangitis.
  • Surgical debulking: Rarely needed; considered when mass effect threatens vital structures or when diagnosis remains uncertain.
  • Plasmapheresis: Occasionally used in severe renal involvement to remove circulating IgG4.

Lifestyle & Supportive Care

  • Calcium and vitamin D supplementation if prolonged steroids are used.
  • Bone density monitoring (DEXA scan) to detect osteoporosis.
  • Vaccinations: influenza annually, pneumococcal, and COVID‑19, especially before immunosuppression.

Living with IgG4‑related disease

Managing IgG4‑RD is a partnership between you, your specialists, and primary care provider.

Self‑Monitoring

  • Keep a symptom diary – note new swellings, pain, or changes in organ function.
  • Track medication side effects (weight gain, mood changes, blood pressure).
  • Schedule regular blood work (CBC, liver/kidney panels, IgG4 levels) as advised.

Medication Adherence

Do not abruptly stop steroids or rituximab; tapering schedules are crucial to avoid rebound disease.

Physical Activity

  • Low‑impact aerobic exercise (walking, swimming) 150 minutes per week improves bone health and reduces steroid‑related weight gain.
  • Strength training twice weekly helps maintain muscle mass.

Nutrition

  • High‑calcium, high‑vitamin D diet (dairy, leafy greens, fortified foods).
  • Limit sodium if on steroids to reduce hypertension risk.
  • Balanced protein intake supports healing of fibrotic tissue.

Psychosocial Support

Chronic illness can affect mental health. Consider counseling, support groups, or patient organizations such as the IgG4‑Related Disease Foundation.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, you can lower the risk of disease flares and complications:

  • Maintain regular follow‑up with a rheumatologist or immunologist.
  • Control comorbid conditions (diabetes, hypertension) that may exacerbate organ damage.
  • Avoid unnecessary long‑term steroid use without specialist supervision.
  • Promptly treat infections; immunosuppressed patients are more vulnerable.

Complications

If untreated or inadequately controlled, IgG4‑RD can cause permanent organ damage.

  • Pancreatic insufficiency: Diabetes mellitus, malabsorption, chronic pain.
  • Renal failure: Tubulointerstitial nephritis leading to end‑stage kidney disease.
  • Aortic aneurysm or dissection: High mortality if rupture occurs.
  • Obstructive cholangitis or biliary cirrhosis.
  • Vision loss: From optic nerve compression in orbital disease.
  • Fibrosis of affected organs: Irreversible scarring despite therapy.

When to Seek Emergency Care

Warning Signs That Require Immediate Medical Attention

  • Sudden, severe abdominal pain, especially with vomiting or jaundice – possible pancreatitis or biliary obstruction.
  • Acute shortness of breath, chest pain, or coughing up blood – may indicate pulmonary involvement or aortic injury.
  • Rapidly enlarging neck or facial swelling causing difficulty breathing or swallowing.
  • Sudden loss of vision or double vision that worsens quickly – orbital compression.
  • High fever (>38.5 °C) with chills, especially if you are on immunosuppressive therapy – risk of infection.
  • New onset of severe headache, weakness, or numbness on one side of the body – possible central nervous system involvement.

If any of these symptoms occur, call 911 or go to the nearest emergency department right away.

References: Mayo Clinic. “IgG4‑related disease.” 2024; CDC. “Autoimmune Diseases Overview.” 2023; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “IgG4‑Related Disease.” 2024; WHO. “Classification of Fibrosing Disorders.” 2022; Cleveland Clinic. “IgG4‑Related Disease: Diagnosis and Management.” 2023; Stone JH et al. *N Engl J Med*. 2012; 366: 539‑551; Kawano M et al. *Lancet*. 2020; 395: 1807‑1819.

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References